tbuckley/cabot-search huggingface dataset:
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial
Authors: Lihui Zhang, Yunliang Zhang, Sheng'ai Shen, Xueying Wang, Luling Dong, Qiuyun Li, Weidong Ren, Yufeng Li, Jianling Bai, Qiuhong Gong, Hongyu Kuang, Lin Qi, Qiang Lu, Wenli Cheng, Yanjie Liu, Shuang Yan, Donghong Wu, Hui Fang, Fang Hou, Yingju Wang, Zhixia Yang, Xu Lian, Jianling Du, Ningling Sun, Linong Ji, Guangwei Li, Lihui Zhang, Yunliang Zhang, Sheng'ai Shen, Xueying Wang, Luling Dong, Qiuyun Li, Weidong Ren, Yufeng Li, Jianling Bai, Hongyu Kuang, Lin Qi, Qiang Lu, Wenli Cheng, Yanjie Liu, Shuang Yan, Donghong Wu, Hui Fang, Ningling Sun, Linong Ji, Guangwei Li, Fang Hou, Yingju Wang, Zhixia Yang, Xu Lian, Jianling Du, Ping Tu, Su Wang, Xinhua Yin, Wenjia Chen, Qing He, Zhongyan Shan, Xueqin Wang, Jinrong Liang, Chang Liu, Yun Xie, Binhong Duan, Wenbo Wang, Zhengnan Gao, Li Li, Lijuan Jiang, Huimin Han, Xiaoping Chen, Li Sun, Bo Feng, Lingling Cao, Xinfang Wang, Xiaoping Chen, Tong Zhang, Xiaoyan Liu, Qiuhong Gong
Journal: The Lancet Diabetes & Endocrinology (2023)
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
Authors: Meletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, Nelson Leung, Joseph Mikhael, Simon J Harrison, Efstathios Kastritis, Laurent Garderet, Alessandro Gozzetti, Niels W C J van de Donk, Katja C Weisel, Ashraf Z Badros, Meral Beksac, Jens Hillengass, Mohamad Mohty, P Joy Ho, Ioannis Ntanasis-Stathopoulos, Maria-Victoria Mateos, Paul Richardson, Joan Blade, Philippe Moreau, Jesus San-Miguel, Nikhil Munshi, S Vincent Rajkumar, Brian G M Durie, Heinz Ludwig, Evangelos Terpos
Journal: The Lancet Oncology (2023)
Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial
Authors: Marius Svanevik, Jolanta Lorentzen, Heidi Borgeraas, Rune Sandbu, Birgitte Seip, Asle W Medhus, Jens K Hertel, Ronette L Kolotkin, Milada C Småstuen, Dag Hofsø, Jøran Hjelmesæth
Journal: The Lancet Diabetes & Endocrinology (2023)
Addressing the childhood cancer crisis in sub-Saharan Africa
Authors: Joseph Lubega, Lulu Chirande, Barnabas Atwine, Alan Davidson, Heronima J Kashaigili, Aimable Kanyamuhunga, Robert K Langat, Deogratias Munube, Rizine Mzikamanda, Ruth Namazzi, Irene Nzamu, Anne Akullo, Carl Allen, Julie M Gastier-Foster, Marilyn Hockenberry, Nmazuo Ozuah, Peter Wasswa, Rachel Smith, Kristi Wilson-Lewis, David G Poplack
Journal: The Lancet Oncology (2023)
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial
Authors: Christian Taucher, Rajeka Lazarus, Hanna Dellago, Gabriele Maurer, Petronela Weisova, Irena Corbic-Ramljak, Katrin Dubischar, Anders Lilja, Susanne Eder-Lingelbach, Romana Hochreiter, Juan Carlos Jaramillo, Helga Junker, Michael Krammer, Petra Pusic, Benedicte Querton, Julian Larcher-Senn, Markus Hoffmann, Stefan Pöhlmann, Adam Finn
Journal: Journal of Infection (2023)
Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients
Authors: Mahesh V. Madhavan, Susheel K. Kodali, Vinod H. Thourani, Raj Makkar, Michael J. Mack, Samir Kapadia, John G. Webb, David J. Cohen, Howard C. Herrmann, Mathew Williams, Kevin Greason, Philippe Pibarot, Rebecca T. Hahn, Wael Jaber, Ke Xu, Maria Alu, Craig R. Smith, Martin B. Leon
Journal: Journal of the American College of Cardiology (2023)
In HF with secondary mitral regurgitation, transcatheter mitral valve repair reduced HF hospitalizations at 5 y
Authors: Chirag Bavishi
Journal: Annals of Internal Medicine (2023)

Source Citation Stone GW, Abraham WT, Lindenfeld J, et al; COAPT Investigators. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388:2037-2048. 36876756
In ischemic stroke, adding EVT to usual care at 6 to 24 h improved functional status at 90 d
Authors: Barnet Eskin
Journal: Annals of Internal Medicine (2023)

Source Citation Olthuis SGH, Pirson FAV, Pinckaers FME, et al; MR CLEAN-LATE investigators. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet. 2023;401:1371-1380. 37003289
In RA, new use of JAK inhibitors was associated with nonmelanoma skin cancer vs. TNF inhibitors at 2 y
Authors: Ami Schattner
Journal: Annals of Internal Medicine (2023)

Source Citation Huss V, Bower H, Hellgren K, et al; ARTIS group. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Ann Rheum Dis. 2023;82:911-919. 36868796
Effects of U.S. State Medical Cannabis Laws on Treatment of Chronic Noncancer Pain
Authors: Emma E. McGinty, Kayla N. Tormohlen, Nicholas J. Seewald, Mark C. Bicket, Alexander D. McCourt, Lainie Rutkow, Sarah A. White, Elizabeth A. Stuart
Journal: Annals of Internal Medicine (2023)

State medical cannabis laws may lead patients with chronic noncancer pain to substitute cannabis in place of prescription opioid or clinical guideline-concordant nonopioid prescription pain medications or procedures.To assess effects of state medical cannabis laws on receipt of prescription opioids, nonopioid prescription pain medications, and procedures for chronic noncancer pain.Using data from 12 states that implemented medical cannabis laws and 17 comparison states, augmented synthetic control analyses estimated laws' effects on receipt of chronic noncancer pain treatment, relative to predicted treatment receipt in the absence of the law.United States, 2010 to 2022.583 820 commercially insured adults with chronic noncancer pain.Proportion of patients receiving any opioid prescription, nonopioid prescription pain medication, or procedure for chronic noncancer pain; volume of each treatment type; and mean days' supply and mean morphine milligram equivalents per day of prescribed opioids, per patient in a given month.In a given month during the first 3 years of law implementation, medical cannabis laws led to an average difference of 0.05 percentage points (95% CI, -0.12 to 0.21 percentage points), 0.05 percentage points (CI, -0.13 to 0.23 percentage points), and -0.17 percentage points (CI, -0.42 to 0.08 percentage points) in the proportion of patients receiving any opioid prescription, any nonopioid prescription pain medication, or any chronic pain procedure, respectively, relative to what we predict would have happened in that month had the law not been implemented.This study used a strong nonexperimental design but relies on untestable assumptions involving parallel counterfactual trends. Statistical power is limited by the finite number of states. Results may not generalize to noncommercially insured populations.This study did not identify important effects of medical cannabis laws on receipt of opioid or nonopioid pain treatment among patients with chronic noncancer pain.National Institute on Drug Abuse.
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Authors: Javier Morales, Yehuda Handelsman
Journal: Journal of the American College of Cardiology (2023)

Chronic kidney disease (CKD) and cardiovascular disease (CVD) have a significant inter-relationship in patients with diabetes. Controlling blood pressure, dyslipidemia, and glucose levels is a common treatment approach to managing CVD risk in patients with CKD and diabetes; despite strict control, however, a high residual risk remains. This review focuses on patients who require pharmacotherapy, in whom new and existing cardiorenal therapies (renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists) with differing mechanisms of action and safety profiles can reduce cardiovascular risk beyond the outcomes achieved with blood pressure, dyslipidemia, or glycemic control alone. Several treatment guidelines have been updated recently to reflect new evidence. Studies of these cardiorenal agents used in combination are ongoing, and results are awaited with interest, with the hope that potential synergistic effects may lead to further improvements in cardiovascular outcomes.
Effect of treatment interruptions on overall survival in patients with triple-negative breast cancer
Authors: Ronald Chow, Shaakir Hasan, J Isabelle Choi, Jana Fox, Arpit M Chhabra, Deborah C Marshall, Richard L Bakst, Charles B Simone
Journal: JNCI Journal of the National Cancer Institute (2023)

Currently, there are no data regarding the impact of treatment interruptions during radiotherapy for breast cancer. In this study, we examine the correlation between treatment interruptions during radiotherapy and outcomes in triple-negative breast cancer patients.
Cumulative incidence of anal cancer since HIV or AIDS diagnosis in the United States
Authors: Cameron B Haas, Eric A Engels, Marie-Josèphe Horner, Ruth M Pfeiffer, Qianlai Luo, Aimée R Kreimer, Joel M Palefsky, Meredith S Shiels
Journal: JNCI Journal of the National Cancer Institute (2023)

Treatment of screen-detected anal high-grade squamous intraepithelial lesions has been shown to effectively reduce the incidence of invasive anal cancer in people with HIV. We provide population-based estimates of cumulative incidence of anal cancer by risk group and age at HIV or AIDS diagnosis. The 0- to 10-year cumulative incidence of anal cancer for men who have sex with men and are younger than 30 years of age at HIV diagnosis was 0.17% (95% confidence interval [CI] = 0.13% to 0.20%) compared with 0.04% (95% CI = 0.02% to 0.06%) in other men and 0.03% (95% CI = 0.01% to 0.04%) in women. For men who have sex with men and have a diagnosis of AIDS and are younger than 30 years of age, the 0- to 10-year cumulative incidence was 0.35% (95% CI = 0.28% to 0.41%). Among people with HIV, men who have sex with men are at the greatest risk of anal cancer, and those with a diagnosis of AIDS had higher risk than those without AIDS. These estimates may inform recommendations for priority populations that could benefit most from anal cancer screening and treatment.
Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8<sup>+</sup>T cells against tumor
Authors: Kanako Shimizu, Shogo Ueda, Masami Kawamura, Honoka Aoshima, Mikiko Satoh, Jun Nakabayashi, Shin-ichiro Fujii
Journal: Journal for ImmunoTherapy of Cancer (2023)

A key to success of cancer immunotherapy is the amplification and sustenance of various effector cells. The hallmark of prominent antitumor T cells is their long-term effector function. Although interleukin (IL)-2 is an attractive cytokine, several attempts have been made towards developing IL-2 modalities with improved effectiveness and safety that enhance natural killer (NK) cells or T cells in cancer models. However, whether such IL-2 modalities can simultaneously support long-term innate and adaptive immunity, particularly stem-like memory, has not been shown. To resolve this issue, we compared the antitumor cellular mechanism with two IL-2/anti-IL-2 complexes (IL-2Cxs) administered in combination with a therapeutic cancer vaccine, which we had previously established as an in vivo dendritic cell-targeting therapy.Two types of IL-2Cxs, CD25-biased IL-2Cx and CD122-biased IL-2Cx, together with a Wilms' tumor 1-expressing vaccine, were evaluated in a leukemic model. The immunological response and synergistic antitumor efficacy of these IL-2Cxs were then evaluated.When CD25-biased or CD122-biased IL-2Cxs in combination with the vaccine were assessed in an advanced-leukemia model, the CD122-biased IL-2Cx combination showed 100% survival, but the CD25-biased IL-2Cx did not. We first showed that invariant natural killer T (NKT) 1 cells are predominantly activated by CD122-biased IL-2Cx. In addition, in-depth analysis of immune responses by CD122-biased IL-2Cx in lymphoid tissues and the tumor microenvironment revealed a dramatic increase in the distinct subsets of NK and CD8+ T cells with stem-like phenotype (CD27+Sca-1hi, CXCR3hi, CD127+TCF-1+T-bet+ Eomes+). Moreover, CD122-biased IL-2Cx combination therapy maintained long-term memory CD8+ T cells capable of potent antitumor protection. After the high dimensional profiling analysis of NK and CD8+T cells, principal component analysis revealed that the stem-like-NK cell and stem-like-CD8+T cell state in the combination were integrated in the same group.CD122-biased IL-2Cx combined with the vaccine can induce a series of reactions in the immune cascade, including activation of not only NKT1 cells, but also NK and CD8+ T cells with a stem-like memory phenotype. Since it can also lead to a long-term, strong antitumor response, the combination of CD122-biased IL-2Cx with a vaccine may serve as a potential and competent strategy for patients with advanced cancer.
Inducibility of Short-Coupled Purkinje Ectopy by Pharmacological Tests in Patients With Spontaneous Short-Coupled Idiopathic Ventricular Fibrillation
Authors: Michel Haissaguerre, Josselin Duchateau, Mikael Laredo, Thomas Lavergne, Pierre F. Winum, Ghassen Cheniti, Xavier Waintraub, Sophie Samson, Elodie Surget, Romain Tixier, Frederic Sacher, Eloi Marijon, Olivier Bernus, Estelle Gandjbakhch
Journal: Circulation (2023)
Incidence of primary large vessel vasculitis in Norfolk, UK from 2011 to 2020
Authors: Chetan B Mukhtyar, Clare Beadsmoore, Fiona L Coath, Georgina Ducker, Sarah Fordham, Katherine Sisson, Cee Y Yong, Richard A Watts
Journal: Annals of the Rheumatic Diseases (2023)

Objectives To report the annual incidence of primary large vessel vasculitis (LVV) in the adult population of Norfolk County, UK, including giant cell arteritis (GCA) (in those ≥50 years) and Takayasu arteritis (TAK). Methods Individuals diagnosed by histology or imaging who lived in NR1-NR30 postcode districts were included. Validated criteria from 1990 and 2022 were applied for final classification. Population data were available from the Office of National Statistics, UK. Results 270 individuals were diagnosed with primary LVV over 4.7 million person-years. The annual incidence (95% CI) of primary LVV was 57.5 (50.8, 64.7)/million person-years in the adult population. 227 and 244 individuals were diagnosed with GCA over ~2.5 million person-years using 1990 and 2022 criteria, respectively. The annual incidence (95% CI) of GCA was 91.6 (80.0, 104.3)/million person-years aged ≥50 years using 1990 criteria and 98.4 (86.4, 111.6)/million person-years aged ≥50 years using 2022 criteria. 13 and 2 individuals were diagnosed with TAK over 4.7 million person-years. The annual incidence (95% CI) of TAK was 2.8 (1.5, 4.7)/million person-years using 1990 criteria and 0.4 (0.0, 1.4)/million person-years using 2022 criteria, in the adult population. The incidence of GCA rose sharply in 2017 coincident with the introduction of a fast-track pathway and fell during the pandemic when the pathway was disrupted. Conclusions This is the first study that reports the incidence of objectively verified primary LVV in the adult population. The incidence of GCA may be affected by the availability of diagnostic pathways. The use of the 2022 classification criteria results in a rise in the classification of GCA and fall in that of TAK.
<i>Circulation</i> Editors and Editorial Board
Authors: Joseph Hill, Joshua Beckman, Dallas Jarett, D Berry, Tyler Emmanouil, S Brilakis, Mercedes Carnethon, Kelly Chin, Dallas Sandeep, R Das, Deborah Diercks, Dallas Eschenhagen, Brendan Hamburg, Justin Everett, Jane Ezekowitz, Shinya Ferguson, Gerald Kanagawa, Dallas Greil, Graeme Dallas, Perth Hankey, Iris Richmond, Stefan Boston, Amit James, Dallas Khera, Dallas Kumbhani, S Carolyn, Sergio Lam, Mark Santiago, Dallas Link, J Charles, Chang-Sheng Lowenstein, Nicholas Ma, Ntobeko Mills, Town Cape, Oslo Omland, Los Ping, Wendy Angeles, Anand Post, Dallas Rohatgi, Hesham Ottawa, Dallas Sadek, Giacomo Gabriele, Berlin Schiattarella, H Svati, Durham Shah, Viskin Sami, Tel Aviv, Wanpen Vongpatanasin, Dallas Karol, E Watson, Los Angeles, Ian Neeland, Satyam Sarma, Vlad Zaha, Parag Joshi, Tracy Hampton, Bridget Kuehn, Michael Fischbein, Marc Ruel, Case Series, Justin Cme, Jeomi Okwara, Monika Sanghavi, Jennifer Thibodeau, José Joglar, Global Rounds, Paul Armstrong, Jeffrey Saffitz, Maryjane Farr, Vanessa Blumer, Pishoy Gouda, Xiaoming Jia, Michael Tre, Martyn Peder, Langeland Myhre, Vera Bittner, Gianluigi Condorelli, Frans Van De Werf, François Abboud, Eugene Braunwald, Bernard Gersh, Helen Hobbs, Eric Olson, Milton Packer, John Rutherford, Colby Ayers, Stacia Desantis, Sue Duval, Julia Kozlitina, Chao Xing, Gabriele Schiattarella, Dan Tong, Carolyn Lam, W Hundley, James De Lemos, Darren Mcguire, Sana Al-Khatib, Victoria Delgado, Philippe Steg, Christopher Semsarian, Robert Gropler, Sunil Rao, Brahmajee Nallamothu, Nancy Sweitzer
Journal: Circulation (2023)
Clonal dynamics and copy number variants by single‐cell analysis in leukemic evolution of myeloproliferative neoplasms
Authors: Laura Calabresi, Chiara Carretta, Simone Romagnoli, Giada Rotunno, Sandra Parenti, Matteo Bertesi, Niccolò Bartalucci, Sebastiano Rontauroli, Chiara Chiereghin, Sara Castellano, Giulia Gentili, Chiara Maccari, Fiorenza Vanderwert, Francesco Mannelli, Matteo Della Porta, Rossella Manfredini, Alessandro Maria Vannucchi, Paola Guglielmelli
Journal: American Journal of Hematology (2023)

Transformation from chronic (CP) to blast phase (BP) in myeloproliferative neoplasm (MPN) remains poorly characterized, and no specific mutation pattern has been highlighted. BP-MPN represents an unmet need, due to its refractoriness to treatment and dismal outcome. Taking advantage of the granularity provided by single-cell sequencing (SCS), we analyzed paired samples of CP and BP in 10 patients to map clonal trajectories and interrogate target copy number variants (CNVs). Already at diagnosis, MPN present as oligoclonal diseases with varying ratio of mutated and wild-type cells, including cases where normal hematopoiesis was entirely surmised by mutated clones. BP originated from increasing clonal complexity, either on top or independent of a driver mutation, through acquisition of novel mutations as well as accumulation of clones harboring multiple mutations, that were detected at CP by SCS but were missed by bulk sequencing. There were progressive copy-number imbalances from CP to BP, that configured distinct clonal profiles and identified recurrences in genes including NF1, TET2, and BCOR, suggesting an additional level of complexity and contribution to leukemic transformation. EZH2 emerged as the gene most frequently affected by single nucleotide and CNVs, that might result in EZH2/PRC2-mediated transcriptional deregulation, as supported by combined scATAC-seq and snRNA-seq analysis of the leukemic clone in a representative case. Overall, findings provided insights into the pathogenesis of MPN-BP, identified CNVs as a hitherto poorly characterized mechanism and point to EZH2 dysregulation as target. Serial assessment of clonal dynamics might potentially allow early detection of impending disease transformation, with therapeutic implications.
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
Authors: Kieran F. Docherty, Kirsty McDowell, Paul Welsh, Joanna Osmanska, Inder Anand, Rudolf A. de Boer, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Eileen O’Meara, Piotr Ponikowski, Morten Schou, David D. Berg, Marc S. Sabatine, David A. Morrow, Petr Jarolim, Ann Hammarstedt, Mikaela Sjöstrand, Anna Maria Langkilde, Scott D. Solomon, Naveed Sattar, Pardeep S. Jhund, John J.V. McMurray
Journal: Journal of the American College of Cardiology (2023)

Elevated circulating carbohydrate antigen 125 (CA125) is a marker of congestion and a predictor of outcomes in acute heart failure (HF). Less is known about CA125 in chronic ambulatory HF with reduced ejection fraction. This study examined the association between baseline CA125 (and changes in CA125) and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; NCT03036124) trial and its relationship with the effect of dapagliflozin. The primary outcome was a composite of a first episode of worsening HF or cardiovascular death. CA125 was measured at baseline and 12 months following randomization. Median baseline CA125 was 13.04 U/mL (IQR: 8.78-21.13 U/mL) in 3,123 of 4,774 patients with available data. Compared with CA125 ≤35 U/mL (upper limit of normal), patients with CA125 >35 U/mL were at a higher risk of the primary outcome (adjusted HR: 1.59; 95% CI: 1.29-1.96). The adjusted risks of the primary outcome relative to quartile 1 (Q1) (≤8.78 U/mL) were as follow: Q2, 8.79-13.04 U/mL (HR: 0.94; 95% CI: 0.71-1.24); Q3, 13.05-21.13 U/mL (HR: 1.22; 95% CI: 0.94-1.59); Q4, ≥21.14 U/mL (HR: 1.63; 95% CI: 1.28-2.09). The beneficial effect of dapagliflozin compared with placebo on the primary outcome was consistent whether CA125 was analyzed in quartiles (interaction P = 0.13) or as a continuous variable (interaction P = 0.75). The placebo-corrected relative change in CA125 at 12 months was −5.2% (95% CI: −10.6% to 0.5%; P = 0.07). In DAPA-HF, elevated CA125 levels were an independent predictor of the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of worsening HF or cardiovascular death regardless of baseline CA125.
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events
Authors: Felice Gragnano, Davide Cao, Leah Pirondini, Anna Franzone, Hyo-Soo Kim, Moritz von Scheidt, Alf-Åge R. Pettersen, Qiang Zhao, Mark Woodward, Mauro Chiarito, Eugene P. McFadden, Kyung Woo Park, Adnan Kastrati, Ingebjørg Seljeflot, Yunpeng Zhu, Stephan Windecker, Jeehoon Kang, Heribert Schunkert, Harald Arnesen, Deepak L. Bhatt, Philippe Gabriel Steg, Paolo Calabrò, Stuart Pocock, Roxana Mehran, Marco Valgimigli
Journal: Journal of the American College of Cardiology (2023)